Compare Boston Beer Company Inc (SAM) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Beer Company Inc vs Zoetis Inc — how do they compare? Boston Beer Company Inc trades at $171.2 (market cap $1.73B), while Zoetis Inc trades at $73.02 (market cap $29.57B). The key difference: Zoetis Inc is far larger — about 17.1× Boston Beer Company Inc's market cap, and Zoetis Inc pays a 2.96% dividend while Boston Beer Company Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Boston Beer Company Inc for 59 Days and Zoetis Inc for 70 Days on average.
| SAM | ZTS | |
|---|---|---|
Market Cap | $1.73B | $29.57B |
Volume | 196,621 | 4,128,093 |
Sector | Consumer Staples | Health |
52-Week High | $260.05 | $147.53 |
52-Week Low | $161.08 | $69.09 |
Typical Hold Time | 59 Days | 70 Days |
Enterprise Value | $1.50B | $37.13B |
Dividend Yield | — | 2.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Beer Company (SAM) trades at $168.16, down 1.3% with a neutral technical outlook. The stock shows mixed fundamentals with a P/E of 22.66 and P/S of 0.92, but negative net income margin of -3.64% and ROE of -8.61%. Recent earnings missed expectations in Q1 and Q2 2026, though Q4 2025 beat estimates. The company maintains positive operating cash flow of $270M in 2025 while expanding brand innovation with new product launches and marketing initiatives.
SAM faces headwinds from volume declines and cost pressures, but brand investments and new product categories offer growth potential. Analyst consensus is cautious with 72% hold ratings, though the $204.44 price target suggests 22% upside. Key risks include competitive pressures and shifting consumer preferences in the alcoholic beverage market.
Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed quarterly earnings performance - beating expectations in Q2 2026 but missing in Q1. Strong fundamentals persist with 71.67% gross margins and 27.69% net income margins, though recent headwinds include U.S. companion animal market weakness and increased competition in key therapeutic areas. The company maintains robust cash flow generation with $2.9 billion from operations in 2025.
Despite near-term pressures, ZTS presents value opportunity with attractive valuation at 11.67 P/E ratio and consensus price target of $87.33 suggesting 22% upside. Risks include ongoing competitive pressures and U.S. market softness, but industry-leading profitability and international growth provide stability. Analyst sentiment remains positive with no sell ratings among 32 covering firms, though technical indicators suggest cautious near-term positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
